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Pilot Study on Interval Colon Cancer: 
Missed colon cancer or fast growth from a sessile serrated polyp?
Colorectal cancer is the third most common cancer diagnosed amongst
men and women, as well as the second leading cause of cancer-related deaths in
the United States1. Early detection and treatment are associated with a better
survival outcome. The American Cancer Society recommends regular screening
procedures, such as a colonoscopy, at age of 50 for both men and women2.
Three distinct molecular pathways have been described in colorectal
cancer3: The APC/Beta-catenin pathway, the microsatellite instability pathway, and
the serrated neoplasia pathway (SNP). Sessile serrated polyps (SSP) (Figure 1)
represent a precursor lesion in 10% of all colorectal cancers and are often
associated with BRAF mutations (over 70% of SSP)3. These lesions occur
commonly in the proximal right side of the colon. SSP polyps are flat lesions that
can be difficult to visualize on colonoscopy screenings. It is hypothesized that early
interval colon cancer after a negative colonoscopy may be a result of missed SSP,
which may have a more rapid progression to neoplasia. BRAF positive colorectal
carcinomas have been associated with old age and are frequently of a higher
grade4. Microsatellite instability and CpG (5’-cytosine-phosphodiester bond-
guanine-3’) island methylation are also associated with the SNP and specifically
with the BRAF mutation in colorectal carcinoma5.
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Microscopic localization of tumor
The diagnosis of invasive carcinoma was confirmed by histologic criteria (Figure
3a). The H and E slides were reviewed and areas representing tumor/invasive
adenocarcinoma were marked for paraffin block macro-dissection. Paraffin
blocks with designated tumors were cut at 5 sections, 10 microns each.
DNA extraction:
The cut sections were submitted for DNA extraction (using the Qiagen protocol)
and subsequent PCR amplification for BRAF detection.
BRAF detection:
The Entrogen BRAF Mutation Analysis Kit was used. It is intended for the
detection of the following BRAF mutations in human genomic DNA at codon 600:
• GTG  GAG (V600E)
• GTG  AAG (V600K)
• GTG  GAT (V600D) 
• The BRAF mutation analysis real-time assay is based on mutation-specific
PCR. Mutation-specific PCR uses primers that are 100% complementary to
mutant variants of the gene. The assay also amplifies an internal control gene
in order to ensure that sufficient amount of DNA is available for amplification.
• The detection of the amplification product is done by using fluorescent
hydrolysis probes. Each probe contains a fluorophore (FAM™ for the mutant
variant of the BRAF gene or VIC® for the internal control gene).
• The probes are complementary to the regions of interest and hybridize to the
template DNA. During the amplification process, DNA polymerase cleaves off
the fluorophore and the quencher from the probe. Upon separation from the
quencher, the fluorescence signal increases dramatically, which is seen by the
instrument detectors.
• The PCR detection instrument used in the study is the Roche LightCycler 480.
• Sensitivity of the assay: the assay is able to detect 1% mutation in a
background of wild-type DNA .
The data from our institution is in accord with previous publications and
demonstrates the propensity of interval colorectal cancer to occur within the right
side of the colon6. It also highlights the association of these cancers with BRAF
mutation, the sessile neoplastic pathway, older age, and female gender7. The
study also supports the hypothesis that interval colorectal carcinoma following a
negative colonoscopy might indicate a missed SSP as the precursor lesion in the
right side of the colon in a significant subset of the cases. Future direction is
aimed at improving the screening process for colorectal carcinoma. Additional
testing includes the possibility of serologic screening and better
preparation/visualization of the right side colon, which may facilitate early
detection of precursor lesions. Enhanced clinical experience with colonoscopies
and awareness of the subtle nature of these precursor lesions may also establish
a better preventive strategy in a subset of the patients.
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The aim of this study is to determine if a BRAF mutation is associated with
interval colorectal cancer in patients who have had a negative colonoscopy within the
preceding 5 years, and therefore may have been associated with an SSP precursor
lesion and/or the SNP pathway. A negative colonoscopy is defined as a colonoscopy
without evidence of any malignancy, clinically and microscopically. The interval time of
the study is between 7 May 2009 and 21 November 2014. 268 patients were identified
with invasive colorectal carcinoma during that time period. Of these, 25 patients (15
females and 10 male) (Figure 2a) fulfilled the inclusion criteria. Patient’s age ranges
were between 56-94 (Figure 2b).
Figure 1. Sessile serrated polyp. Hematoxylin
and Eosin stain, original magnification x10.
Insert: Sessile serrated polyp with saw-tooth
branching crypts and flask-like expansion at the
base, original magnification x 40.
Figure 2a. Patient Gender. Ten males (40%) 
and fifteen females (60%). Figure 2b.  Patient Age.  
Figure 3a. Normal colonic mucosa (yellow 
arrow) transitioning to an invasive 
adenocarcinoma (blue arrow). Hematoxylin and 
Eosin stain, original magnification x 10.
Insert: Invasive adenocarcinoma, original 
magnification x 40. 
Figure 3b. Tumor Location. Location of the 
invasive adenocarcinoma within the patients 






Ten out of twenty-five (40%) of the patients with invasive colorectal
carcinoma had a BRAF V600E mutation (Figure 4a). 80% of these patients were
female (Figure 4b), and 90% of the patients were over the age of 70 (Figure 4c). 70%
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Figure 4a. Total Wild Type vs. Mutant. 
Percentage of patients with a mutation and 
without a mutation. 
Figure 4c. Age of patients with a BRAF 
mutation. 
Figure 4b. Mutation Gender. Gender of 
patients with a BRAF mutation.
Figure 4d. Mutation tumor location. Location of the 
invasive adenocarcinoma within patients that have 
a BRAF mutation. 
